|
| Tuesday, 6 June 2023, 20:00 HKT/SGT | |
| |  | |
Source: GeneTex | |
|
|
|
IRVINE, CA, June 6, 2023 - (ACN Newswire) - GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
Topic: Press release summary
Source: GeneTex
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance
Apr 22, 2026 22:00 HKT/SGT
|
|
|
China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank
Wednesday, April 22, 2026 8:32:00 PM
|
|
|
CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited
Wednesday, April 22, 2026 8:15:00 PM
|
|
|
GMG Appoints New Chief Production Growth Officer and Provides Update on Global Production Plans
Apr 22, 2026 19:59 HKT/SGT
|
|
|
OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC) 
Wednesday, April 22, 2026 6:30:00 PM
|
|
|
TMX Group Announces Agreement to Acquire Cboe Australia and Cboe Canada
Apr 22, 2026 18:29 HKT/SGT
|
|
|
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Apr 22, 2026 18:08 HKT/SGT
|
|
|
MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK
Wednesday, April 22, 2026 4:16:00 PM
|
|
|
Luxury NEV Maker Seres Delivers Sustained Profitability and Strong Dividends
Apr 22, 2026 15:31 HKT/SGT
|
|
|
NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan
Wednesday, April 22, 2026 1:46:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
